Ascendis Pharma A/S (ASND)
Nasdaq: ASND · Pharmaceutical Preparations · filing with the SEC since 2014
Who owns Ascendis Pharma A/S
As filed with the SECHolders of 5% or more
4
T. Rowe Price Investment Management, Inc. holds 10.5% of ADR, as its SCHEDULE 13G/A filed May 7, 2026 says.
Directors and officers
15
report now, of 15 people on the record since 2026. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 4 named at left.
Holders of 5% or moreshare of the class, as filed
T. Rowe Price Investment Management, Inc.
SCHEDULE 13G/A · filed May 7, 2026 · ADR · 9.9% in May 7, 2026
Westfield Capital Management Company, L.P.
SCHEDULE 13G/A · filed Feb 11, 2026 · Common Stock · 9.18% in Feb 11, 2025
Fmr LLC
SCHEDULE 13G/A · filed May 6, 2026 · COMMON STOCK · 8% in May 12, 2025
Janus Henderson Group PLC
SCHEDULE 13G/A · filed May 15, 2026 · American Depositary Shares · 7.8% in Nov 14, 2025
Artisan Partners Asset Management Inc.
SCHEDULE 13G/A · filed Aug 13, 2026 · Ordinary Shares · reported falling below 5%, from 5.2% in Feb 3, 2026
Capital International Investors
SCHEDULE 13G/A · filed May 14, 2026 · Common Stock · reported falling below 5%, from 5.6% in Aug 13, 2025
What ASND reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
V I S E N Pharmaceutical
An investee · associate · invested in, named in the 20-F filed Feb 11, 2026
18 subsidiaries in 11 countries, from the list filed with the 20-F filed Feb 11, 2026.
Insider tradesForm 4
3sales
9purchases
0sales on a scheduled plan
3people selling
$5.5Msold, in dollars
$800,000bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window5 of 15 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Jensen Flemming Steen | EVP & Product Supply and Quality | 1 | $4.6M | 0 | 0 | $0 |
| Bodenhoff Mads | SVP & PAO | 1 | $800,000 | 0 | 0 | $0 |
| Holtug Lars | director | 1 | $100,000 | 0 | 0 | $0 |
| Bienaime Jean Jacques | director | 0 | $0 | 0 | 7 | $700,000 |
| Smith Scott Thomas | EVP & Chief Financial Officer | 0 | $0 | 0 | 2 | $100,000 |